Antibiotic specialist Paratek Pharmaceuticals (NSDQ: PRTK) has secured additional funding from the Biomedical Advanced Research and Development Authority (BARDA) to develop the antibiotic Nuzyra (omadacycline) for anthrax. Specifically, the latest funding will support Paratek’s program to develop the tetracycline-class antibiotic Nuzyra as a post-exposure prophylaxis and pulmonary anthrax treatment. The latest BARDA funding will support…
Paratek reveals Nuzyra data on pneumonia and skin infections
Antibiotic specialist Paratek Pharmaceuticals (NSDQ:PRTK) recently shared new data related to its tetracycline-class antibacterial Nuzyra (omadacycline). Specifically, the company provided real-world data related to pneumonia, skin infections and nontuberculous mycobacterial infections in presentations at IDWeek 2021, a virtual conference organized by several infectious disease associations. The company also has collected data on in vitro activity…